Podbit · Moonshots with Peter Diamandis
XPRIZE has launched $600 million in prizes and catalyzed $30 billion in R&D. The Golden Age Report explicitly endorses prize challenges, advanced market commitments, and pay-for-results models as alternatives to traditional grants — with the administration eyeing prizes in the $100 million range for major national challenges.
Where this was said
At 47:00 · chapter starts 45:55
With the Golden Age Report explicitly endorsing prize challenges and advanced market commitments, Peter steps into his home turf: over 30 years, XPRIZE has launched $600 million in prize competitions and driven approximately $30 billion in R&D — a roughly 50:1 leverage ratio on prize capital. He pitches Kratsios on the idea of 10 $1 billion prizes focused on the nation's most important challenges, including one targeting longevity. Kratsios is enthusiastic but pragmatic: the federal budget can absorb prizes in the $100 million range for sufficiently significant challenges, but $1 billion for a single prize is a stretch for the current fiscal environment. Peter then introduces the $101 million XPRIZE Healthspan — the organization's largest-ever prize, with 830 competing teams — as an example of what's achievable, arguing that reversing aging by 20 functional years would be the single highest-impact intervention on the US economy.
XPRIZE has launched $600 million worth of prize competitions and catalyzed approximately $30 billion in R&D investment as a result.
The US federal government spends approximately $200 billion per year on R&D, with roughly $45 billion of that at NIH for biomedical research.
The XPRIZE Healthspan competition is a $101 million prize with 830 competing teams, aiming to reverse functional age by 20 years.
Social norms compress behavior so effectively that we assume other minds are similar to ours. They almost never are. After running over 100 psychology studies, Greenberg's biggest finding is that humans are far more different from each other than we intuitively believe.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.